A Phase 2 interventional study of Standard Dose - Ibuprofen oral suspension and Precision Dose - Ibuprofen oral suspension in Patent Ductus Arteriosus and Preterm, sponsored by Hamilton Health Sciences Corporation. Recruiting at 1 site in Canada. Open to participants aged Up to 28 Weeks. Per ClinicalTrials.gov, last updated 2025-08-27.
Sponsored by Hamilton Health Sciences Corporation · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Ductus Arteriosus, Patent with a site in Canada — 6 open to participants now, 6 under way, 1 of them phase 3. Ductus Arteriosus, Patent · Canada.
Among the 10 studies in Ductus Arteriosus, Patent with a site in Canada, this one is the only one that started in 2024, is one of 2 in phase 2, and was the 10th registered.
146 studies on the registry are indexed under Ductus Arteriosus, Patent; 21 are open to participants now.
Browse Ductus Arteriosus, Patent studies →6 of the 10 studies in Ductus Arteriosus, Patent with a site in Canada are open now. Recruiting first, the newest first:
Mount Sinai Hospital, Canada · Sites in Canada, Australia, Hong Kong and 1 more country
Ages up to 27 wk
Ottawa Hospital Research Institute · Sites in Canada
Ages up to 29 wk
IWK Health Centre · Sites in Canada, United States
Ages up to 72 hrs
Occlutech International AB · Sites in Canada, France, Italy and 6 more countries
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages 1 min+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 14 Ductus Arteriosus, Patent studies recruiting now, 4 (29%) set no upper age limit and 10 (71%) stop at 75 or younger; 14 take children under 18; 1 takes healthy volunteers.
This study: Up to 28 Weeks · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 2 · Phase 4 1
First in 2008; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 26 is below the median of 80 across 80 interventional studies indexed under Ductus Arteriosus, Patent.
Median enrollment 28 across the 6 interventional studies, 153 across the 4 observational. Of the 3 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 10 have an industry lead sponsor. The 9 most frequent:
Hamilton Health Sciences Corporation is the lead sponsor of 242 studies on the registry; 38 are open to participants now.
Hamilton Health Sciences Corporation has 1 study filed under Ductus Arteriosus, Patent — fewer than ten, so there is no comparison to draw.
1 of the studies in Ductus Arteriosus, Patent with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05340582Mount Sinai Hospital, CanadaCo-administration of Acetaminophen With Ibuprofen to Improve Duct-Related Outcomes in Extremely Premature Infants | 2027-01 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Ductus Arteriosus, Patent with a site in Canada, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Newborns born early are at risk for a serious health problem called patent ductus arteriosus (PDA). PDA is a passageway between heart and lung that can cause life-threatening complications such as bleeding in the brain or even death if it remains open and large. When closure of PDA is needed, doctors make every attempt to do it as soon as possible. Ibuprofen is the best drug to close the PDA, but it only works for 50% of small newborns. The investigators have shown before that small newborns handle ibuprofen differently and the amount of active ibuprofen that reaches their blood can be very unpredictable. Studies have shown if enough ibuprofen reaches the body, it can close the PDA. Therefore the investigators designed this study to see whether it is possible to give each newborn the right amount of ibuprofen that their body needs to close the PDA. The investigators will compare two ways to give ibuprofen in a small number of newborns: 1 - standard amount of ibuprofen to everyone, which is the usual care or 2 - ibuprofen doses that will be changed based on how much active ibuprofen has reached the body and how well the newborn's PDA is closing. The investigators will then compare the number of PDAs closed in each group and closely monitor any possible challenges for this new practice. By doing this project, the goals can be summarized as below:
A. Primary goal: To determine if it is feasible to successfully run a larger study in the future.
B. Secondary goals
Study Design Overview:
This clinical trial is a single-center, pilot, randomized, controlled, triple-blind study designed to evaluate the feasibility and effectiveness of model-informed precision dosing (MIPD) of oral ibuprofen compared to standard dosing for the treatment of Patent Ductus Arteriosus (PDA) in preterm neonates (≤27+6 weeks gestational age). The trial assesses both operational feasibility and clinical outcomes, with a focus on the use of a pharmacokinetic (PK) prediction module provided by the Web-Accessible Population Pharmacokinetics Service-PDA (WAPPS-PDA).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PNA-based standard dosing of ibuprofen \[ \<= 72 hours PNA: 10/5/5 q24hrs vs \>72 hours PNA 20/10/10 q24hrs\].
Drug: Standard Dose - Ibuprofen oral suspension
PNA-based regimen only for the initial dose, the rest of regimen will be guided by a MIPD, using a Web-Accessible Population Pharmacokinetics Service (WAPPS-PDA).
Drug: Precision Dose - Ibuprofen oral suspension
Standard dosing administers ibuprofen without adjustments, starting with an initial loading dose followed by two maintenance doses at 24-hour intervals: 10/5/5 mg/kg for infants aged ≤72 hours, and 20/10/10 mg/kg for those \>72 hours old.
Precision Dosing (Model-Informed Precision Dosing - MIPD): Begins with the same initial loading dose as the Standard Dosing arm, with subsequent doses adjusted based on a Bayesian forecasting model that integrates real-time PK and echocardiographic data.
Recruitment Feasibility
Feasibility will be assessed by the ability to randomize at least 15% of all eligible patients during the study period.
Time frame: From intial dose to 96 hours after.
Timeliness of PK Sample Result Availability
Feasibility will be assessed by the ability to obtain results for at least 80% of pharmacokinetic (PK) samples within 4 hours of sample collection.
Time frame: From initial dose to 96 hours after
Timeliness of Top-up Dosing Data for Intervention Arm
Feasibility will be assessed by the ability to generate dosing data for top-up administration within 14 hours of the previous dose in at least 80% of subjects in the intervention arm.
Time frame: From initial dose to 96 hours after
Timely Completion of Daily Targeted Neonatal Echocardiogram (TnEcho)
Feasibility will be assessed by the ability to perform daily TnEcho within 4 to 8 hours prior to the next scheduled dose in at least 80% of subjects.
Time frame: From initial dose to 96 hours after
Timely TnEcho Scoring and Model-Informed Precision Dosing (MIPD) Recommendation
Feasibility will be assessed by the ability to score the TnEcho, assign responsiveness grouping, and provide the MIPD recommendation for the second and third doses of oral ibuprofen within 24 hours of the previous dose in at least 80% of subjects.
Time frame: From initial dose to 96 hours after
Achievement of Target Trough Concentration and AUC (Intervention Arm Only)
This exploratory outcome will evaluate the proportion of participants in the intervention arm who reach the predefined target trough concentration, AUC₀-₂₄, and AUC₀-₇₂. Results will be summarized descriptively and compared within the intervention group.
Time frame: From first dose to 72 hours
Maximum Ibuprofen Concentration (Cmax) ≤80 µg/mL (Intervention Arm Only)
This outcome will assess the proportion of intervention-arm participants whose maximum ibuprofen concentration (Cmax) remains at or below the predefined limit of 80 µg/mL. Results will be described and compared to the predefined threshold.
Time frame: From first dose to 72 hours
Daily Ibuprofen Dose ≤40 mg/kg (Intervention Arm Only)
This outcome will evaluate the proportion of participants in the intervention arm whose daily ibuprofen dose does not exceed 40 mg/kg. The frequency of participants meeting this dosing threshold will be summarized descriptively.
Time frame: From first dose to 72 hours
Closure of the Patent Ductus Arteriosus (PDA)
This outcome will assess the proportion of participants with echocardiographically confirmed closure of the PDA following treatment. Results will be summarized and compared across study groups.
Time frame: From first dose to 14 days
Need for Repeat Pharmacotherapy
This outcome will evaluate the proportion of participants requiring a repeat course of pharmacologic PDA treatment within 14 days of completing the initial course. Findings will be reported descriptively.
Time frame: From first dose to 14 Days
Need for Surgical Ligation
This outcome will assess the proportion of participants who require surgical ligation of the PDA due to persistent patency or clinical deterioration. Results will be summarized for both study groups.
Time frame: From first dose to 14 Days
Treatment Interruption
This outcome will describe the proportion of participants whose ibuprofen treatment was interrupted prior to completion due to clinical or safety concerns. Outcomes will be compared descriptively.
Time frame: From first dose to 14 Days
Occurrence of Adverse Events
This outcome will describe the proportion of participants who experience at least one adverse event during the follow-up period. Events will be classified by severity and relatedness to the study drug, and summarized descriptively.
Time frame: From first dose to 14 Days
Plan to share: No — This is a pilot feasibility study with a small sample size, and there are no current plans for data sharing.
Started Jul 2024 (actual). Primary completion is estimated for Jul 2026, 24 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hamilton Health Sciences Corporation →